Immune targeting in breast cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• The immune system plays a complex role in breast cancer, influencing tumor growth and immune surveillance.
• Infiltrating immune cells impact patient prognosis and response to therapies.
• Existing breast cancer vaccines have shown limited clinical efficacy.

Purpose of the Study:

• To review the role of the immune system in breast cancer.
• To discuss the potential of immune checkpoint blockade in breast cancer immunotherapy.
• To explore rational combination strategies for improved treatment outcomes.

Main Methods:

• Review of current literature on breast cancer immunology and immunotherapy.
• Analysis of recent clinical responses to immune checkpoint inhibitors.
• Discussion of potential combination immunotherapy approaches.

Main Results:

• Immune checkpoint blockade, including programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) antagonists, has shown objective responses in metastatic triple-negative breast cancer.
• Pembrolizumab and MPDL3280A are examples of agents demonstrating clinical activity.
• The immune system's dual role necessitates careful therapeutic design.

Conclusions:

• Immune checkpoint blockade has renewed interest in breast cancer immunotherapy.
• Combination immunotherapy strategies targeting T cell expansion, trafficking, activity, and immune suppression are crucial.
• Optimized immunotherapy approaches hold promise for long-term disease control and cure in breast cancer.